Product Name

Domperidone

Name: Domperidone - LGM Pharma
SKU: 57808-66-9

CAS Number

57808-66-9

LGM Pharma is an API distributor. LGM Pharma supplies APIs as per CGMP with DMF support, subject to availability and manufacturer requirements. LGM Pharma does not sell or supply APIs or finished dosage products to individual patients, doctors, or pharmacies.

Questions? Call our customer API support number 1-(800)-881-8210

Product Name:

Domperidone

CAS Number:

57808-66-9

Indication:

For management of dyspepsia, heartburn, epigastric pain, nausea, and vomiting.

Mode of Action:

Domperidone acts as a gastrointestinal emptying (delayed) adjunct and peristaltic stimulant. The gastroprokinetic properties of domperidone are related to its peripheral dopamine receptor blocking properties. Domperidone facilitates gastric emptying and decreases small bowel transit time by increasing esophageal and gastric peristalsis and by lowering esophageal sphincter pressure. Antiemetic: The antiemetic properties of domperidone are related to its dopamine receptor blocking activity at both the chemoreceptor trigger zone and at the gastric level. It has strong affinities for the D2 and D3 dopamine receptors, which are found in the chemoreceptor trigger zone, located just outside the blood brain barrier, which – among others – regulates nausea and vomiting

Pharmacodynamics:

Domperidone is a specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms.

Toxicity:

Side effects include galactorrhea, gynecomastia, or menstrual irregularities.

IUPAC:

5-chloro-1-{1-[3-(2-oxo-2, 3-dihydro-1H-1, 3-benzodiazol-1-yl)propyl]piperidin-4-yl}-2, 3-dihydro-1H-1, 3-benzodiazol-2-one

ATC:

A03FA03

PubChem:

3151

DrugBank:

DB01184 (APRD00418)

Formula:

C₈H₁₀N₄O₂

Molecular Mass:

425.911

SMILES:

ClC1=CC2=C(C=C1)N(C1CCN(CCCN3C(=O)NC4=CC=CC=C34)CC1)C(=O)N2

AHFS Code:

56:32.00 56:92.00

InChi:

FGXWKSZFVQUSTL-UHFFFAOYSA-N

General Reference:

Silvers D, Kipnes M, Broadstone V, Patterson D, Quigley EM, McCallum R, Leidy NK, Farup C, Liu Y, Joslyn A: Domperidone in the management of symptoms of diabetic gastroparesis: efficacy, tolerability, and quality-of-life outcomes in a multicenter controlled trial. DOM–USA-5 Study Group. Clin Ther. 1998 May-Jun;20(3):438-53. Pubmed

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

LGM currently offers Monoclonal Antibodies (mAbs) for non-GMP/R&D use. Please inquire about Monoclonal Antibodies produced under GMP conditions.

Questions? Call our customer API support number 1-(800)-881-8210.

Ask us about this product

API’s From Quality Manufacturers:

Streamlined API supply towards initial research stages as well as larger quantities of cGMP material for clinical trials and product commercialization
Premium quality GMP certified and fully accredited API manufacturing plants
Technical packages as well as access to filed DMF, ASMF or CEP (subject to availability)
Regulatory and technical assistance towards any submission type based on specific customer requirements

Domperidone

57808-66-9

Ask us about this product

API’s From Quality Manufacturers:

Find an API Product